These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27836401)

  • 1. Novel bicyclo[3.1.0]hexane analogs as antagonists of metabotropic glutamate 2/3 receptors for the treatment of depression.
    Dressman BA; Tromiczak EG; Chappell MD; Tripp AE; Quimby SJ; Vetman T; Fivush AM; Matt J; Jaramillo C; Li R; Khilevich A; Blanco MJ; Smith SC; Carpintero M; de Diego JE; Barberis M; García-Cerrada S; Soriano JF; Schkeryantz JM; Witkin JM; Wafford KA; Seidel W; Britton T; Overshiner CD; Li X; Wang XS; Heinz BA; Catlow JT; Swanson S; Bedwell D; Ornstein PL; Mitch CH
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5663-5668. PubMed ID: 27836401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.
    Chappell MD; Li R; Smith SC; Dressman BA; Tromiczak EG; Tripp AE; Blanco MJ; Vetman T; Quimby SJ; Matt J; Britton TC; Fivush AM; Schkeryantz JM; Mayhugh D; Erickson JA; Bures MG; Jaramillo C; Carpintero M; Diego JE; Barberis M; Garcia-Cerrada S; Soriano JF; Antonysamy S; Atwell S; MacEwan I; Condon B; Sougias C; Wang J; Zhang A; Conners K; Groshong C; Wasserman SR; Koss JW; Witkin JM; Li X; Overshiner C; Wafford KA; Seidel W; Wang XS; Heinz BA; Swanson S; Catlow JT; Bedwell DW; Monn JA; Mitch CH; Ornstein PL
    J Med Chem; 2016 Dec; 59(24):10974-10993. PubMed ID: 28002967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu
    Witkin JM; Ornstein PL; Mitch CH; Li R; Smith SC; Heinz BA; Wang XS; Xiang C; Carter JH; Anderson WH; Li X; Broad LM; Pasqui F; Fitzjohn SM; Sanger HE; Smith JL; Catlow J; Swanson S; Monn JA
    Neuropharmacology; 2017 Mar; 115():100-114. PubMed ID: 26748052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.
    Monn JA; Prieto L; Taboada L; Hao J; Reinhard MR; Henry SS; Beadle CD; Walton L; Man T; Rudyk H; Clark B; Tupper D; Baker SR; Lamas C; Montero C; Marcos A; Blanco J; Bures M; Clawson DK; Atwell S; Lu F; Wang J; Russell M; Heinz BA; Wang X; Carter JH; Getman BG; Catlow JT; Swanson S; Johnson BG; Shaw DB; McKinzie DL
    J Med Chem; 2015 Sep; 58(18):7526-48. PubMed ID: 26313429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
    Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
    J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
    Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.
    Chaki S; Yoshikawa R; Hirota S; Shimazaki T; Maeda M; Kawashima N; Yoshimizu T; Yasuhara A; Sakagami K; Okuyama S; Nakanishi S; Nakazato A
    Neuropharmacology; 2004 Mar; 46(4):457-67. PubMed ID: 14975669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential.
    Yasuhara A; Nakamura M; Sakagami K; Shimazaki T; Yoshikawa R; Chaki S; Ohta H; Nakazato A
    Bioorg Med Chem; 2006 Jun; 14(12):4193-207. PubMed ID: 16487713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
    J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.
    Hughes ZA; Neal SJ; Smith DL; Sukoff Rizzo SJ; Pulicicchio CM; Lotarski S; Lu S; Dwyer JM; Brennan J; Olsen M; Bender CN; Kouranova E; Andree TH; Harrison JE; Whiteside GT; Springer D; O'Neil SV; Leonard SK; Schechter LE; Dunlop J; Rosenzweig-Lipson S; Ring RH
    Neuropharmacology; 2013 Mar; 66():202-14. PubMed ID: 22551786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture.
    Ahnaou A; Dautzenberg FM; Geys H; Imogai H; Gibelin A; Moechars D; Steckler T; Drinkenburg WH
    Eur J Pharmacol; 2009 Jan; 603(1-3):62-72. PubMed ID: 19046965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabotropic glutamate receptors in the control of mood disorders.
    Witkin JM; Marek GJ; Johnson BG; Schoepp DD
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):87-100. PubMed ID: 17430147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes.
    Fell MJ; Witkin JM; Falcone JF; Katner JS; Perry KW; Hart J; Rorick-Kehn L; Overshiner CD; Rasmussen K; Chaney SF; Benvenga MJ; Li X; Marlow DL; Thompson LK; Luecke SK; Wafford KA; Seidel WF; Edgar DM; Quets AT; Felder CC; Wang X; Heinz BA; Nikolayev A; Kuo MS; Mayhugh D; Khilevich A; Zhang D; Ebert PJ; Eckstein JA; Ackermann BL; Swanson SP; Catlow JT; Dean RA; Jackson K; Tauscher-Wisniewski S; Marek GJ; Schkeryantz JM; Svensson KA
    J Pharmacol Exp Ther; 2011 Jan; 336(1):165-77. PubMed ID: 20947638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
    Marek GJ; Wright RA; Schoepp DD; Monn JA; Aghajanian GK
    J Pharmacol Exp Ther; 2000 Jan; 292(1):76-87. PubMed ID: 10604933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are compounds acting at metabotropic glutamate receptors the answer to treating depression?
    Palucha A
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1545-53. PubMed ID: 17107280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists.
    Koike H; Iijima M; Chaki S
    Neuropharmacology; 2011 Dec; 61(8):1419-23. PubMed ID: 21903115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2.
    Brugel TA; Smith RW; Balestra M; Becker C; Daniels T; Koether GM; Throner SR; Panko LM; Brown DG; Liu R; Gordon J; Peters MF
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5405-10. PubMed ID: 20719509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamate-Based Drug Discovery for Novel Antidepressants.
    Pałucha-Poniewiera A; Pilc A
    Expert Opin Drug Discov; 2016 Sep; 11(9):873-83. PubMed ID: 27409299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mGlu2/3 receptor antagonists.
    Chaki S
    Adv Pharmacol; 2019; 86():97-120. PubMed ID: 31378257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutagenesis and molecular modeling of the orthosteric binding site of the mGlu2 receptor determining interactions of the group II receptor antagonist (3)H-HYDIA.
    Lundström L; Kuhn B; Beck J; Borroni E; Wettstein JG; Woltering TJ; Gatti S
    ChemMedChem; 2009 Jul; 4(7):1086-94. PubMed ID: 19402024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.